A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2)
暂无分享,去创建一个
Kazuhiro Yoshida | T. Yoshikawa | E. Oki | Yoon-Koo Kang | N. Sugimoto | K. Muro | M. Azuma | Y. Hamamoto | Y. Iwamoto | Li‐Tzong Chen | T. Satoh | Ken Kato | H. Fujii | T. Nakajima | Y. Omuro | S. Fushida | N. Boku | K. Minashi | T. Nishina | T. Tamura | S. Saitoh | K. Yamaguchi | Y. Komatsu | A. Tsuji | M. Tsuda | T. Esaki | M. Goto | N. Machida | K. Taku | K. Kunieda | K. Chin